Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Eder et al. [38] 1999 CR 1/6 PA 0/1 48 100% (1/1)
100% (6/6) 		100% (1/1)
100% (1/1) 		Mean: 1.38 100% (1/1)
NR 		NR
Ella et al. [39] 2011 CR 1/2 PA 0/1 48 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		NR NR NR
Ergun et al. [40] 2010 CR 1/6 PA+SLE 0/1 24 100% (1/1)
100% (6/6) 		100% (1/1)
100% (5/5) 		NR NR NR
Overall
PA - CR: 3 3/14 - Ratio: 0/3 Mean: 40 100% (3/3)
100% (14/14) 		100% (3/3)
100% (7/7) 		Mean: 1.38 100% (1/1)
NR 		NR

a = weighted mean or median.
ADs = autoimmune diseases; CR = case report; M/F = male/female; N = number; NR = not reported; PI = peri-implantitis; SLE = systemic lupus erythematosus.